These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 6268955)

  • 1. Protectivity of herpes simplex virus antigens: studies in mice on the adjuvant effect of PICLC and on the dependence of protection on T cell competence.
    Hilfenhaus J; Christ H; Köhler R; Moser H; Kirchner H; Levy HB
    Med Microbiol Immunol; 1981; 169(4):225-35. PubMed ID: 6268955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of a virion envelope herpes simplex virus vaccine against experimental skin infections in hairless mice.
    Klein RJ; Buimovici-Klein E; Moser H; Moucha R; Hilfenhaus J
    Arch Virol; 1981; 68(2):73-80. PubMed ID: 6264897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Herpes simplex virus subunit vaccine: characterization of the virus strain used and testing of the vaccine.
    Hilfenhaus J; Moser H; Herrmann A; Mauler R
    Dev Biol Stand; 1982; 52():321-31. PubMed ID: 6299841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody responses and protection in mice immunized with herpes simplex virus type 1 antigen immune-stimulating complex preparations.
    Ertürk M; Jennings R; Hockley D; Potter CW
    J Gen Virol; 1989 Aug; 70 ( Pt 8)():2149-55. PubMed ID: 2769234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The proportion of herpes simplex virus-specific cytotoxic T lymphocytes (Tc) that recognize glycoprotein C varies between individual mice and is dependent on the form of immunization.
    Martin S; Mercadal CM; Weir JP; Rouse BT
    Viral Immunol; 1993; 6(1):21-33. PubMed ID: 8386515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.
    Rooney JF; Wohlenberg C; Cremer KJ; Moss B; Notkins AL
    J Virol; 1988 May; 62(5):1530-4. PubMed ID: 2833606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes.
    Manickan E; Rouse RJ; Yu Z; Wire WS; Rouse BT
    J Immunol; 1995 Jul; 155(1):259-65. PubMed ID: 7602102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection of mice against herpes simplex virus infection by a Lactobacillus casei preparation (LC 9018) in combination with inactivated viral antigen.
    Watanabe T; Saito H
    Microbiol Immunol; 1986; 30(2):111-22. PubMed ID: 3012292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems.
    Mohamedi SA; Brewer JM; Alexander J; Heath AW; Jennings R
    Vaccine; 2000 Apr; 18(20):2083-94. PubMed ID: 10715522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in humoral immunogenicity between herpes simplex virus types 1 and 2.
    Kampe P; Knoblich A; Dietrich M; Falke D
    J Gen Virol; 1985 Oct; 66 ( Pt 10)():2215-23. PubMed ID: 2995556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens.
    Karem KL; Bowen J; Kuklin N; Rouse BT
    J Gen Virol; 1997 Feb; 78 ( Pt 2)():427-34. PubMed ID: 9018066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response.
    Bettahi I; Zhang X; Afifi RE; BenMohamed L
    Viral Immunol; 2006; 19(2):220-36. PubMed ID: 16817765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute and latent herpes simplex virus neurological disease in mice immunized with purified virus-specific glycoproteins gB or gD.
    Dix RD; Mills J
    J Med Virol; 1985 Sep; 17(1):9-18. PubMed ID: 2995573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Helper T cells induced by an immunopurified herpes simplex virus type I (HSV-I) 115 kilodalton glycoprotein (gB) protect mice against HSV-I infection.
    Chan WL; Lukig ML; Liew FY
    J Exp Med; 1985 Oct; 162(4):1304-18. PubMed ID: 2995536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with chaperone-peptide complex induces low-avidity cytotoxic T lymphocytes providing transient protection against herpes simplex virus infection.
    Kumaraguru U; Gierynska M; Norman S; Bruce BD; Rouse BT
    J Virol; 2002 Jan; 76(1):136-41. PubMed ID: 11739679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine adjuvant effects, and immune response, to synthetic polymers MVE and poly ICLC.
    Chirigos MA; Welker R; Schlick E; Saito T; Ruffmann R
    Prog Clin Biol Res; 1984; 161():467-79. PubMed ID: 6483899
    [No Abstract]   [Full Text] [Related]  

  • 18. Escherichia coli-derived envelope protein gD but not gC antigens of herpes simplex virus protect mice against a lethal challenge with HSV-1 and HSV-2.
    Bröker M; Abel KJ; Köhler R; Hilfenhaus J; Amann E
    Med Microbiol Immunol; 1990; 179(3):145-59. PubMed ID: 2169577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Latent HSV-1 infection in mice immunized with a zwitterionic detergent-extracted HSV-1 antigen preparation.
    al-Ghamdi A; Jennings R; Bentley H; Potter CW
    Arch Virol; 1989; 108(1-2):19-31. PubMed ID: 2556982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCL10/CXCR3-Dependent Mobilization of Herpes Simplex Virus-Specific CD8
    Srivastava R; Khan AA; Chilukuri S; Syed SA; Tran TT; Furness J; Bahraoui E; BenMohamed L
    J Virol; 2017 Jul; 91(14):. PubMed ID: 28468883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.